The impact of antiproteinuric therapy on the prothrombotic state in patients with overt proteinuria

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 12, 2011, Pages 2416-2423

  Mahmoodi, B K ^a   Mulder, A B ^a   Waanders, F ^a   Spronk, H M H ^b   Mulder, R ^a   Slagman, M C J ^a   Vogt, L ^a   Navis, G ^a   Ten Cate, H ^b   Kluin Nelemans, H C ^a   Laverman, G D ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Losartan; Nephritic syndrome; Proteinuria; Prothrombotic state; Thrombin generation

Indexed keywords

ANTICOAGULANT PROTEIN; BLOOD CLOTTING FACTOR 8; DIURETIC AGENT; FIBRINOGEN; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SODIUM RESTRICTION; THROMBIN TIME;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOSARTAN; MALE; MIDDLE AGED; PLACEBOS; PROTEINURIA; PROTHROMBIN; THROMBOSIS;

EID: 82755161997     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04525.x     Document Type: Article

References (23)

1. Mahmoodi BK, ten Kate MK, Waanders F, Veeger NJ, Brouwer JL, Vogt L, Navis G, van der Meer J. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 2008; 117: 224-30.
2. Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int 1985; 28: 429-39.
3. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993; 44: 638-42.
4. Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res 2006; 118: 397-407.
5. Alkjaersig N, Fletcher AP, Narayanan M, Robson AM. Course and resolution of the coagulopathy in nephrotic children. Kidney Int 1987; 31: 772-80.
6. Schlegel N. Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost 1997; 23: 271-80.
7. Colle JP, Mishal Z, Lesty C, Mirshahi M, Peyne J, Baumelou A, Bensman A, Soria J, Soria C. Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications: a possible mechanism for the high thrombotic tendency? Thromb Haemost 1999; 82: 1482-9.
8. Kanfer A, Kleinknecht D, Broyer M, Josso F. Coagulation studies in 45 cases of nephrotic syndrome without uremia. Thromb Diath Haemorrh 1970; 24: 562-71.
9. Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int 1994; 46: 287-96.
10. Mahmoodi BK, Gansevoort RT, Veeger NJ, Matthews AG, Navis G, Hillege HL, van der Meer J. Microalbuminuria and risk of venous thromboembolism. JAMA 2009; 301: 1790-7.
11. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-61.
12. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
13. Hoyer PF, Gonda S, Barthels M, Krohn HP, Brodehl J. Thromboembolic complications in children with nephrotic syndrome. Risk and incidence. Acta Paediatr Scand 1986; 75: 804-10.
14. Kendall AG, Lohmann RC, Dossetor JB. Nephrotic syndrome. A hypercoagulable state. Arch Intern Med 1971; 127: 1021-7.
15. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999-1007.
16. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Béguin S. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-53.
17. Dielis AW, Balliel WM, van Oerle R, Hermens WT, Spronk HM, ten Cate H, Hamulyák K. Thrombomodulin-modified thrombin generation after in vivo recombinant factor VIII treatment in severe hemophilia A. Haematologica 2008; 93: 1351-7.
18. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med 1985; 312: 1544-8.
19. Dielis AW, Castoldi E, Spronk HM, van Oerle R, Hamulyák K, ten Cate H, Rosing J. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008; 6: 125-31.
20. Wichers IM, Tanck MW, Meijers JC, Lisman T, Reitsma PH, Rosendaal FR, Büller HR, Middeldorp S. Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. Thromb Haemost 2009; 101: 465-70.
21. Segers O, van Oerle R, ten Cate H, Rosing J, Castoldi E. Thrombin generation as an intermediate phenotype for venous thrombosis. Thromb Haemost 2010; 103: 114-22.
22. Kauffmann RH, Veltkamp JJ, van Tilburg NH, van Es LA. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 1978; 65: 607-13.
23. Vaziri ND, Paule P, Toohey J, Hung E, Alikhani S, Darwish R, Pahl MV. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Arch Intern Med 1984; 144: 1802-3.